A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, multi-center, active-controlled, double-blind,
double-dummy, multicenter, non-inferiority study comparing the clinical efficacy, safety and
tolerability of ProF-001 to fluconazole.